skip to Main Content

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

When compared with nab-paclitaxel (Abraxane), fluorouracil (5-FU)/leucovorin or gemcitabine led to objective responses in 35% of patients. The (5-FU)/leucovorin group exceeded the prespecified goal of a 4-month progression-free survival (PFS) rate of 50%.1 Additionally, patients randomized to the 5-FU/leucovorin regimen had a 12-month survival rate of 48% versus 41% for gemcitabine-containing therapy. The 18-month survival of the 5-FU/leucovorin group was more than twice that of the gemcitabine arm.  Read more . . .

Back To Top